Creative Medical Technology (CELZ) S-1/A 23 Nov 21 IPO registration (amended) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2021
Cover [Abstract]
Entity Registrant Name	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001187953
Document Type	S-1/A
Amendment Flag	true
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Filer Category	Non-accelerated Filer
Entity Ex Transition Period	false
Amendment Description	Amendment
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	87-0622284
Entity Address Address Line 1	211 E Osborn Road
Entity Address City Or Town	Phoenix
Entity Address State Or Province	AZ
Entity Address Postal Zip Code	85012
City Area Code	833
Local Phone Number	336-7636

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash	$ 2,377,930	$ 98,012	$ 88,648
Related party advance	200,000	0
Accounts receivable			5,600
Total Current Assets	2,577,930	98,012	94,248
OTHER ASSETS
Other assets	3,282	0
Licenses, net of amortization	550,700	619,763	436,555
TOTAL ASSETS	3,131,912	717,775	530,803
CURRENT LIABILITIES
Accounts payable	454,525	350,899	320,785
Accrued expenses	29,920	159,771	120,492
Management fee and patent liabilities - related parties	250,082	468,782	240,082
Convertible notes payable, net of discount of $0 and $409,649, respectively	0	788,701	1,062,266
Notes payable, net of discount of $2,219,430 and $0, respectively	2,743,430	0
Advances from related party	17,300	10,800	10,800
Derivative liabilities	0	38,741,832	6,847,877
Total Current Liabilities	3,495,257	40,520,785	8,602,302
TOTAL LIABILITIES		40,520,785	8,602,302
STOCKHOLDERS' DEFICIT
Preferred Stock Value		0	0
Common Stock Value	2,458	1,537	45
Additional paid-in capital	38,434,192	22,082,689	17,490,462
Accumulated deficit	(38,802,995)	(61,890,236)	(25,565,006)
TOTAL STOCKHOLDERS' DEFICIT	(363,345)	(39,803,010)	(8,071,499)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	3,131,912	717,775	530,803
Preferred Stock Series C [Member]
STOCKHOLDERS' DEFICIT
Preferred Stock Value	0	0	3,000
Preferred Stock Series A [Member]
STOCKHOLDERS' DEFICIT
Preferred Stock Value	3,000	$ 3,000	$ 3,000
Preferred Stock Series B [Member]
STOCKHOLDERS' DEFICIT
Preferred Stock Value	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt discount, convertible notes payable	$ 120,185	$ 409,649	$ 560,899
Common stock, shares par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	6,000,000,000	12,000,000,000	1,200,000,000
Common stock, shares issued	2,458,250	1,537,081	44,986
Common stock, shares outstanding	2,458,242	1,537,073	44,978
Preferred stock, shares par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	7,000,000	7,000,000	7,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred Stock Series A [Member]
Preferred stock, shares par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000	3,000,000
Preferred stock, shares issued	3,000,000	3,000,000	3,000,000
Preferred stock, shares outstanding	3,000,000	3,000,000	3,000,000
Preferred Stock Series B [Member]
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred Stock Series C [Member]
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500	500
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 10,000	$ 77,000	$ 20,000	$ 147,000	$ 164,500	$ 165,500
Cost of revenues	4,000	17,600	8,500	42,596	50,596	45,499
Gross profit	6,000	59,400	11,500	104,404	113,904	120,001
OPERATING EXPENSES
Research and development	59,180	0	59,180	0
Selling, general and administrative	757,235	285,100	1,536,479	846,154	1,161,947	1,223,219
Amortization of patent costs	23,021	16,771	69,063	50,021	66,792	26,950
TOTAL EXPENSES	839,436	301,871	1,664,722	896,175	1,228,739	1,250,169
Operating loss	(833,436)	(242,471)	(1,653,222)	(791,771)	(1,114,835)	(1,130,168)
OTHER INCOME/(EXPENSE)
Interest expense	1,305,273	289,210	1,875,687	910,236	1,229,590	1,895,528
Gain on extinguishment of convertible notes	489,157	0	585,601	0		(366,042)
Change in fair value of derivatives liabilities	(194,044)	926,532	26,030,549	3,996,775	(33,980,805)	(5,091,935)
Total other income (expense)	(1,010,160)	637,322	24,740,463	3,086,539	(35,210,395)	(7,353,505)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	(1,843,596)	394,851	23,087,241	2,294,768	(36,325,230)	(8,483,673)
Provision for income taxes	0	0	0
NET INCOME (LOSS)	$ (1,843,596)	$ 394,851	$ 23,087,241	$ 2,294,768	$ (36,325,230)	$ (8,483,673)
BASIC NET INCOME (LOSS) PER SHARE	$ (0.75)	$ 0.58	$ 9.98	$ 6.21	$ (62.69)	$ (410.12)
DILUTED NET INCOME (LOSS) PER SHARE	$ (0.75)	$ 0.14	$ 9.77	$ 1.07
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC	2,452,076	684,983	2,313,005	369,423
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED	2,452,076	2,725,722	2,363,145	2,138,913
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED					579,461	20,686

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 23,087,241	$ 2,294,768	$ (36,325,230)	$ (8,483,673)
Adjustments to reconcile net income to net cash from operating activities:
Stock-based compensation	595,380	68,242	170,323	0
Amortization	69,063	50,021	66,792	26,950
Amortization of debt discounts	1,755,104	804,898	979,960	1,723,451
Change in fair value of derivatives liabilities	(26,030,549)	(3,996,775)	33,980,805	5,091,935
Increase in principal and accrued interest balances due to penalty provision	93,821	0
Loss on extinguishment of convertible notes payable			0	266,042
Excess consideration issued in connection with relieve of management fees and patent liability			0	100,000
Gain on extinguishment of convertible notes	(585,601)	0
Changes in assets and liabilities:
Accounts receivable	0	5,600	5,600	4,000
Inventory	0	0
Accounts payable	103,626	23,666	30,114	(11,054)
Accrued expenses	26,169	126,838	167,029	189,256
Management fee payable	(168,700)	131,200	490,051	(120,000)
Net cash used in operating activities	(1,054,446)	(491,542)	(434,556)	(1,213,093)
CASH FLOWS FROM INVESTING ACTIVITIES:
Advance to related party	(200,000)	0
Net cash used in investing activities	(200,000)		(250,000)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from note payable	3,887,750	0	710,920	1,302,795
Payments on notes payable	(105,000)	0
Payments on notes payable to related party				(50,000)
Payment of debt issuance costs	(443,239)
Payment of deferred offering costs	(3,282)
Payments on convertible notes payable	0	(17,000)	(17,000)	(263,411)
Proceeds from convertible notes payable	435,040	458,600	710,920	1,302,795
Prepayment premiums paid on convertible notes payable				(41,699)
Proceeds from sale of preferred stock	462,000	0
Payments to settle convertible notes payable and warrants	(705,405)	0
Related party advances	226,500
Repayment of related party advances	(220,000)
Net cash provided from financing activities	3,534,364	441,600	693,920	997,685
NET INCREASE (DECREASE) IN CASH	2,279,918	(49,942)	9,364	(215,408)
BEGINNING CASH BALANCE	98,012	88,648	88,648	304,056
ENDING CASH BALANCE	2,377,930	38,706	98,012	88,648
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	9,186	6,000	6,000	18,177
Cash payments for income taxes	0	0	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of notes payable, accrued interest and derivative liabilities into common stock	13,747,415	2,772,149	4,162,045	4,156,811
Accrued dividends on preferred stock	27,725	0
Warrants issued with notes payable and as a service fee	2,097,629	0
Related party liability incurred for additional patent costs			0	300,000
Beneficial conversion feature issued with Allogenics patent liability			101,351	0
Conversion of management fees and patent liability into common stock	50,000	160,000	$ 160,000	$ 138,000
Discounts on convertible notes payable due to derivative liabilities	134,640	0
Exchange of preferred stock for notes payable	$ 572,275	$ 0

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series A Preferred Stock [Member]	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2018				3,000,000	12,036
Balance, amount at Dec. 31, 2018	$ (3,994,637)			$ 3,000	$ 12	$ 13,083,684	$ (17,081,333)
Common stock issued for cashless warrant exercise, shares	1,062				1,063
Common stock issued for cashless warrant exercise, amount	$ 0			0	$ 1	(1)	0
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares					23,746
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	1,501,275			0	$ 24	1,501,251	0
Common stock issued for related party management fee and patent liabilities, shares					8,133
Common stock issued for related party management fee and patent liabilities, amount	250,000			0	$ 8	249,992	0
Relief of derivative liabilities	2,655,536			0	0	2,655,536	0
Net loss	(8,483,673)			$ 0	$ 0	0	(8,483,673)
Beneficial conversion feature issued with Allogenics patent liability	0
Stock-based compensation	0
Balance, shares at Dec. 31, 2019				3,000,000	44,978
Balance, amount at Dec. 31, 2019	(8,071,499)	$ 0	$ 0	$ 3,000	$ 45	17,490,462	(25,565,006)
Net loss	2,294,768	0	0	0	$ 0	0	2,294,768
Common stock issued for related party management liabilities, shares					128,630
Common stock issued for related party management liabilities, amount	160,000	0	0	0	$ 129	159,871	0
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares					777,865
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	1,033,418	0	0	0	$ 778	1,032,640	0
Relief of derivative liabilities	1,738,731	0	0	0	0	1,738,731	0
Stock-based compensation	68,242	0	0	0	$ 0	68,242	0
Difference in shares from reverse stock split, shares					3
Difference in shares from reverse stock split, amount	0	0	0	$ 0	$ 0	0	0
Stock-based compensation	68,242
Balance, shares at Sep. 30, 2020				3,000,000	951,476
Balance, amount at Sep. 30, 2020	(2,776,340)	0	0	$ 3,000	$ 952	20,489,946	(23,270,238)
Balance, shares at Dec. 31, 2019				3,000,000	44,978
Balance, amount at Dec. 31, 2019	(8,071,499)	0	0	$ 3,000	$ 45	17,490,462	(25,565,006)
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares					681,731,395
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	1,366,705			0	$ 1,363	1,365,342	0
Common stock issued for related party management fee and patent liabilities, shares					128,630
Common stock issued for related party management fee and patent liabilities, amount	160,000			0	$ 129	159,871	0
Relief of derivative liabilities	2,795,340			0	0	2,795,340	0
Net loss	(36,325,230)			0	0	0	(36,325,230)
Beneficial conversion feature issued with Allogenics patent liability	101,351				0	101,351	0
Stock-based compensation	170,323			0	$ 0	170,323	0
Differences in shares from reverse stock split, shares					1,293
Differences in shares from reverse stock split, amount	0			$ 0	$ 0	0	0
Balance, shares at Dec. 31, 2020				3,000,000	1,537,073
Balance, amount at Dec. 31, 2020	(39,803,010)	0	0	$ 3,000	$ 1,537	22,082,689	(61,890,236)
Balance, shares at Jun. 30, 2020				3,000,000	490,644
Balance, amount at Jun. 30, 2020	(4,204,672)	0	0	$ 3,000	$ 491	19,456,926	(23,665,089)
Net loss	394,851	0	0	0	$ 0	0	394,851
Common stock issued for related party management liabilities, shares					84,656
Common stock issued for related party management liabilities, amount	40,000	0	0	0	$ 85	39,915	0
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares					376,176
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	428,162	0	0	0	$ 376	427,786	0
Relief of derivative liabilities	497,077	0	0	0	0	497,077	0
Stock-based compensation	68,242	0	0	$ 0	$ 0	68,242	0
Balance, shares at Sep. 30, 2020				3,000,000	951,476
Balance, amount at Sep. 30, 2020	(2,776,340)	0	0	$ 3,000	$ 952	20,489,946	(23,270,238)
Balance, shares at Dec. 31, 2020				3,000,000	1,537,073
Balance, amount at Dec. 31, 2020	$ (39,803,010)	0	0	$ 3,000	$ 1,537	22,082,689	(61,890,236)
Common stock issued for cashless warrant exercise, shares	43,167
Net loss	$ 23,087,241	0	0	0	$ 0	0	23,087,241
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares					789,727
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	1,383,331	0	0	0	$ 790	1,382,541	0
Relief of derivative liabilities	12,364,084	0	0	0	0	12,364,084	0
Stock-based compensation	595,380	$ 0	$ 0	0	$ 0	595,380	0
Stock-based compensation	595,380
Proceeds from sales of preferred stock, shares		350	150		4,286
Proceeds from sales of preferred stock, amount	462,000	$ 321,000	$ 141,000	0	$ 4	(4)	0
Common stock issued for related party patent and management liabilities, shares					89,286
Common stock issued for related party patent and management liabilities, amount	50,000	0	0	0	$ 89	49,911	0
Dividends on preferred stock	(27,725)	0	0	0	$ 0	(27,725)	0
Cashless exercise of warrants, shares					37,870
Cashless exercise of warrants, amount	0	0	0	0	$ 38	(38)	0
Warrants issued with notes payable	2,097,629	$ 0	$ 0	0	0	2,097,629	0
Preferred stock redemption, shares		(350)	(150)
Preferred stock redemption, amount	(572,275)	$ (321,000)	$ (141,000)	$ 0	$ 0	(110,275)	0
Balance, shares at Sep. 30, 2021				3,000,000	2,458,242
Balance, amount at Sep. 30, 2021	(363,345)	$ 0	$ 0	$ 3,000	$ 2,458	38,434,192	(38,802,995)
Balance, shares at Jun. 30, 2021		350	150	3,000,000	2,440,614
Balance, amount at Jun. 30, 2021	(714,453)	$ 321,000	$ 141,000	$ 3,000	$ 2,440	35,777,506	(36,959,399)
Net loss	(1,843,596)	0	0	0	$ 0	0	(1,843,596)
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares					17,628
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	153,980	0	0	0	$ 18	153,962	0
Relief of derivative liabilities	138,731	0	0	0	0	138,731	0
Stock-based compensation	383,612	0	0	0	0	383,612	0
Dividends on preferred stock	(6,973)	0	0	0	0	(6,973)	0
Warrants issued with notes payable	2,097,629	$ 0	$ 0	0	0	2,097,629	0
Preferred stock redemption, shares		(350)	(150)
Preferred stock redemption, amount	(572,275)	$ (321,000)	$ (141,000)	$ 0	$ 0	(110,275)	0
Balance, shares at Sep. 30, 2021				3,000,000	2,458,242
Balance, amount at Sep. 30, 2021	$ (363,345)	$ 0	$ 0	$ 3,000	$ 2,458	$ 38,434,192	$ (38,802,995)

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization – Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments. Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AmnioStem LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AmnioStem LLC have commenced commercial activities. We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem ® ® ® ® In addition to our CaverStem ® ® ® ® In 2020, through our ImmCelz Inc. subsidiary, we began exploring the development of treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties that may be suitable for the treatment of stroke victims, among other indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration. Use of Estimates Basis of Presentation September September Going Concern nine-month September $1,054,446 $917,327 In August were and is being used to fund operations - . If the Company raises additional funds through offerings of shares of common stock or other securities, such offerings would cause dilution of current stockholders’ percentage ownership in the Company, which could be substantial. Future offerings could also have a material and adverse effect on the price of the Company’s common stock. On September 28, 2021, the Company filed a Registration Statement on Form S-1 with the Securities and Exchange Commission to raise capital through the offer and sale of units consisting of shares of common stock and warrants to purchase additional shares of common stock in a firm commitment underwriting to be conducted by Roth Capital Partners. However, there can be no assurance that the Company will be successful in completing the offering. The securities to be sold in the offering may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective Risks and Uncertainties Revenue Fair Value of Financial Instruments When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September Notes Warrants Total Derivative liability at December 31, 2020 $ 37,343,835 $ 1,397,997 $ 38,741,832 Addition of new conversion option derivatives 1,077,757 - 1,077,757 Extinguishment/modification (726,998 ) (346 ) (727,344 ) Conversion of note derivatives (10,494,316 ) (1,869,768 ) (12,364,084 ) Change in fair value (27,200,278 ) 472,117 (26,728,161 ) Derivative liability at September $ - $ - $ - Basic and Diluted Loss Per Share – The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the nine-months September For the Three Months Ended September 30, 2020 For the Nine Months Ended September 30, 2021 For the Nine Months Ended September 30, 2020 Weighted average common shares outstanding used in calculating basic earnings per share 684,983 2,313,005 369,423 Effect of Series B and C preferred stock - - - Effect of warrants 47,784 50,140 56,313 Effect of convertible notes payable 1,579,107 - 1,307,727 Effect of convertible related party management fee and patent liabilities 413,896 - 413,896 Weighted average common shares outstanding used in calculating diluted earnings per share 2,452,076 2,363,145 2,138,913 Net income as reported $ 394,851 $ 23,087,241 $ 2,294,768 Add - Interest on convertible notes payable 28,228 - 105,338 Net income available to common stockholders $ 423,079 $ 23,087,241 $ 2,400,106 Diluted income per Share $ 0.16 $ 9.77 $ 1.12 The Company excluded 7 18 nine-months September During the three-month period ended September 7 481,351 September The Company excluded 7options and 17,842 warrants from the computation of diluted net income per share for the three-months ended September 30, 2020 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period. The Company excluded 7 options and 413 warrants from the computation of diluted net income per share for the nine-months ended September 30, 2020 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period. On November 10, 2021, we effected a 1-for-500 reverse split of our authorized and issued and outstanding shares of common stock. All share references have been restated for this reverse split to the earliest period presented. As a result of the split, the authorized shares of the Company’s common stock decreased to 50,000,000 shares. Recent Accounting Pronouncements	NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing amniotic stem cells, and the treatment of neurologic disorders and lower back pain using various types of stem cells through its AmnioStem LLC, StemSpine, LLC, and ImmCelz, Inc. subsidiaries. However, neither AmnioStem LLC, StemSpine, Inc. nor ImmCelz, Inc. have commenced commercial activities. Risks and Uncertainties On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time consuming and could delay launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones. Use of Estimates Basis of Presentation U.S. GAAP Going Concern Concentration Risks Cash Equivalents Fair Value of Financial Instrument Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: Notes Warrants Total Derivative liability at December 31, 2019 $ 6,659,055 $ 188,822 $ 6,847,877 Addition of new conversion option derivatives 2,572,723 - 2,572,723 Extinguishment/modification - - - Conversion of note derivatives (2,795,340 ) - (2,795,340 ) Change in fair value 30,907,397 1,209,175 32,116,572 Derivative liability at December 31, 2020 $ 37,343,835 $ 1,397,997 $ 38,741,832 Intangible Assets Impairment Derivative Liabilities As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2020 and 2019, as disclosed in Notes 4 and 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification), and the change in fair value is recorded on our consolidated statement of operations. Revenue The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer. Payments received for which the earnings process is not yet complete are deferred. As of December 31, 2020, the Company had deferred revenue of $32,000 included within current liabilities in the accompanying consolidated balance sheet. Research and Development 1. Erectile Dysfunction Technology based upon the use of stem cells. These costs, which consist primarily of monies paid for clinical trial expenses, materials and supplies and compensation costs amounted to $0 for the year ended December 31, 2020. There were $0 in research costs for the period ended December 31, 2019; 2. Amniotic Fluid-based Stem Cells. Pre-clinical research costs, which consist primarily of monies paid for laboratory space, materials and supplies amounted to $0 for the year ended December 31, 2020. There were $0 in research costs for the period ended December 31, 2019. Stock-Based Compensation Income Taxes The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The Company will recognize interest and penalties related to unrecognized tax benefits in the income tax provision in the accompanying statement of operations. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income taxes paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of relevant risks, facts and circumstances existing at that time. To the extent that the assessment of such tax positions change, the change in estimate is recorded in the period in which the determination is made. Basic and Diluted Loss Per Share 7 152,738 7 10,089 Recent Accounting Pronouncements

LICENSING AGREEMENTS

LICENSING AGREEMENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
LICENSING AGREEMENTS
NOTE 2 - LICENSING AGREEMENTS	NOTE 2 – LICENSING AGREEMENTS ED Patent $7,479 nine-month September September $43,481 Multipotent Amniotic Fetal Stem Cells License Agreement September The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expenses of $293 and $879 nine-month September $293 $882 nine-month September September $4,670 Lower Back Patent · The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment. · In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH: o $100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial. o $200,000, upon completion of the IRB clinical trial. o $300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial. · In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH: o $100,000 upon filing an IND with the FDA. o $200,000 upon dosing of the first patient in a Phase 1-2 clinical trial. o $400,000 upon dosing the first patient in a Phase 3 clinical trial. · Payment may be made in cash or shares of our common at a discount of 30% to the recent trading price. · In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles. · For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties. The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $2,500 and $7,500 nine-month September September $57,500 In November 2019, following a successful international pilot study, the Company elected to initiate commercialization of the StemSpine procedure using autologous stem cells. As a result, the Company is obligated to pay CMH $300,000 pursuant to the Patent Purchase Agreement as described above. During the nine-months September 89,286 September $34,455 nine-month September $34,455 nine-month September September $213,799 ImmCelz TM TM TM · Licensee shall pay Licensor a license fee of 250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $1.85, · Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelzTM. during such calendar quarter (the “Continuing Royalty”) · in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets. As a result, the Company is obligated to pay Jadi $250,000 pursuant to the Patent License Agreement as described above. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $6,250 and $18,750 nine-month September nine-month September September $231,250	NOTE 2 – LICENSING AGREEMENTS ED Patent 862 Multipotent Amniotic Fetal Stem Cells License Agreement The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $1,172 was recorded for the years ended December 31, 2020 and 2019. As of December 31, 2020, the carrying value of the patent was $5,256. The Company expects to amortize approximately $1,172 annually through 2026 related to the patent costs. Lower Back Patent · The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment. · In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH: o $100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial. o $200,000, upon completion of the IRB clinical trial. o $300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial. · In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH: o $100,000 upon filing an IND with the FDA. o $200,000 upon dosing of the first patient in a Phase 1-2 clinical trial. o $400,000 upon dosing the first patient in a Phase 3 clinical trial. · Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date. · In the event the Company’s shares of common stock trade below $5.00 · For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties. The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $10,000 was recorded for the years ended December 31, 2020 and 2019. As of December 31, 2020, the carrying value of the initial patent license was $65,000. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs. In November, 2019, following a successful international pilot study, the Company elected to initiate commercialization of the StemSpine procedure using autologous stem cells. As a result, the Company is obligated to pay CMH $300,000 pursuant to the Patent Purchase Agreement as described above. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $45,940 was recorded for the year ended December 31, 2020. Amortization expense of $5,806 was recorded for the year ended December 31, 2019. As of December 31, 2020, the carrying value of the patent was $248,254. The Company expects to amortize approximately $46,000 annually through 2027 related to the patent costs. ImmCelz™ · Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $1.85 which is based on the date of this agreement · Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”) · in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets. As a result, the Company is obligated to pay Jadi $250,000 pursuant to the Patent License Agreement as described above. Refer to exhibit 10.29 for the complete agreement. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Given the date of the Agreement, there was no amortization expense recorded for the year ended December 31, 2020. As of December 31, 2020, the carrying value of the patent was $250,000. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs. As of December 31, 2020, future expected amortization of these assets is as follows: For the year ended December 31, 2021 93,327 2022 93,327 2023 93,327 2024 93,327 2025 93,327 Thereafter 152,835 Total $ 619,470 The following is a rollforward of the Company’s licensing agreements for the year end December 31, 2020. Assets Accumulated Amortization Balances at December 31, 2019 $ 510,000 $ (73,445 ) Addition of new assets 250,000 - Amortization - (66,792 ) Balances at December 31, 2020 $ 760,000 $ (140,237 )

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
NOTE 3 - RELATED PARTY TRANSACTIONS	NOTE 3 – RELATED PARTY TRANSACTIONS Up until September 15, 2021, the Company was a party to an agreement with CMH under which the Company was obligated to reimburse CMH for services and directors amounts owed to CMH under the agreement were payable CMH provided notice of its exercise of this option. The agreement originally provided for a monthly reimbursement in the amount of $35,000, which amount was increased to $45,000 effective January 1, 2019 September $112,500 and , respectively Following the termination of this agreement with CMH in September 2021, the Company entered into direct employment relationships with its executive officers, and direct consulting arrangements with its non-employee directors. As of September 30, 2021, no amounts were owed to CMH under the terminated agreement. As of December 31, 2020, amounts due to CMH under the arrangement were $18,782. On May 28, 2021 , were repaid in August 2021. See Note 2 for discussion of an additional related party transaction with CMH.	NOTE 3 – RELATED PARTY TRANSACTIONS The Company has incurred a monetary obligation to a related corporation to reimburse the cost of services provided to the Company (management and consulting) through December 31, 2020. Each of the Company’s executive officers is employed by CMH, and will continue to receive his or her salary or compensation from CMH. The Company has an agreement with CMH which obligates the Company to reimburse CMH $35,000 per month for such services beginning January 2016. On November 17, 2017, the Company entered into an amended Management Reimbursement Agreement dated November 17, 2017, with Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, and with Creative Medical Health, Inc., the parent of the Company (“CMH”). The Agreement memorializes the arrangement between the parties whereby the Company has, since January 1, 2016, reimbursed CMH $35,000 per month for the services of management and consultants employed by CMH and performing services for the Company and CMT. At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days’ prior written notice. The agreement was amended in December 2018 to increase the monthly reimbursement from $35,000 to $45,000 effective January 1, 2019 and thereafter. On January 12, 2018, the Company entered into a Debt Settlement Agreement with Timothy Warbington, our CEO, Chairman, and principal shareholder, and Creative Medical Health, Inc., the parent of the Company, whereby Mr. Warbington cancelled $150,000 of debt owed by CMH to him in return for which he would receive 3,000,000 shares of Series A Preferred Stock which CMH agreed to receive in return for cancellation of $150,000 of debt owed by us to CMH for management reimbursement costs. As of December 31, 2020, and 2019, amounts due to CMH under the arrangement were $18,782 and $82 respectively. During 2016, the Company entered into three note payable agreements with CMH in which the proceeds were used in operations. The notes payable were dated February 2, 2016, May 1, 2016 and May 18, 2016 and resulted in borrowings of $50,000, $50,000 and $25,000, respectively. Notes payable of $50,000 mature on April 30, 2018, $50,000 on July 31, 2018 and $25,000 on May 18, 2018. On May 4, 2017, CMT and CMH entered into a Note Extension and Limited Waiver Agreement whereby the parties extended the maturity date of the 8% Promissory Note dated February 2, 2016, in the principal amount of $50,000, from April 30, 2017, to April 30, 2018, and CMH waived the nonpayment of the Note by CMT on the original maturity date. On extension, CMT paid to CMH accrued interest related to the extended note of $4,050. On July 31, 2017, CMT and CMH entered into a Note Extension and Limited Waiver Agreement whereby the parties extended the maturity date of the 8% Promissory Note dated May 1, 2016, in the principal amount of $50,000, from July 31, 2017, toJuly 31, 2018, and CMH waived the nonpayment of the Note by CMT on the original maturity date. On extension, CMT paid to CMH accrued interest related to the extended note of $4,050. The notes incur interest at 8% per annum on the outstanding balance of the notes. As of December 31, 2020, accrued, unpaid interest was $0. On April 11, 2018, CMH converted $136,003 of principal and accrued interest into 19,711 On August 12, 2016, CMH advanced the Company $2,000 for operations. The amount is due on demand and does not incur interest. On May 17, 2017, StemSpine, LLC (“StemSpine”), a newly formed Nevada limited liability company and wholly owned subsidiary of Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, entered into a Patent Purchase Agreement dated May 17, 2017 (the “Agreement”), with Creative Medical Holdings, Inc. (“CMH”). To date, the Company has paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000cash payment and the issuance of 667 133 84,656 On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a Board Member. Execution of the agreement triggered a $250,000 payment obligation to Jadi. See Note 2 for discussion of an additional related party transactions with CMH relating the purchase of our ED patent in 2016, our StemSpine® patent in 2017 and the ImmCelz™ Patent License agreement in 2020.

DEBT

DEBT	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
DEBT
NOTE 4 - DEBT	NOTE 4 – DEBT On August 11, 2021, we completed the sale of 15% Original Issue Discount Senior Notes (“Bridge Notes”) in the aggregate principal amount of $4,456,176 to a group of institutional investors (the “Purchasers”). In connection with the sale of the Bridge Notes, holders of our shares of Series B Preferred Stock and Series C Preferred Stock exchanged such preferred stock for additional Bridge Notes in the aggregate principal amount of $690,000. The Bridge Notes mature on February 11, 2022, subject to the requirement that we redeem the Bridge Notes prior to such date with the net proceeds of any future offering of our securities. The Notes do not bear interest other than upon an event of default, and are not convertible into the Company’s common stock. In addition, the Notes are subject to covenants, events of defaults and other terms and conditions customary in transactions of this nature. The Company is amortizing the on-issuance discount and financing fees totaling $758,426 to interest expense with respect to these notes. The Company also issued to the purchasers of the Bridge Notes five-year warrants to purchase an aggregate of 363,046 shares of our common stock at an initial exercise price of $14.175 per share, subject to anti-dilution adjustment in the event of future sales of our equity below the then exercise price, stock dividends, stock splits and other specified events. Roth Capital Partners (“Roth”), acted as sole placement agent for the offering. Pursuant to terms of an engagement letter with Roth, the Company paid Roth a placement agent fee in the amount $312,750. The Company also issued Roth a warrant to purchase 20,189 shares of common stock with the same terms as the warrants issued to the Purchasers. During the nine-months September also $498,800 $435,040, which have since been repaid in full were to and July bore a were amortized $443,905 with respect to these notes On May 28, 2021, Mr. Timothy Warbington, who is our CEO and Chairman; and , who is a director of ours were repaid during the quarter ended September 30, did bore at the per annum On June 21, 2021, we issued a $105,000, non-convertible note to an accredited investor with net proceeds of $100,000. The note was repaid during the quarter ended 30, did bore at the per annum During the nine-months September $1,755,104 $804,898 September $0. During the nine-months September 789,727 1,383,331 notes, 37,870 43,167 nine-months September 777,865 $1,033,418 During the nine-months September 23,000 with no pre-payment premiums As of September For the year ended December 31, 2021 0 2022 5,146,176 Total $ 5,146,176	NOTE 4 – DEBT During 2019, we issued $1,572,400 in convertible notes to accredited investors with net proceeds of $1,302,795. The notes matured from February through October of 2020 and bore interest rates ranging from 2% to 11%. In February 2019, we entered into three separate exchange agreements with holders of common stock purchase warrants issued by the Company in September 2018 and November 2018. Under each exchange agreement, the Company issued a convertible promissory note in the principal amount of $100,000 to the warrant holder party to such exchange agreement in exchange for the cancellation of common stock purchase warrants held by such warrant holder, initially exercisable for an aggregate of 43 During 2019, the Company issued an aggregate of 23,746 1,062 1,188 During the year ended December 31, 2019, the Company incurred $41,699 in pre-payment premiums associated with the extinguishment of $313,111 in principal During 2020, we issued $831,140 in convertible notes to accredited investors with net proceeds of $710,920. The notes mature from February through December of 2021 and bear an interest rate of 8%. The notes are convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices of the Company’s common stock during the previous 15 trading days preceding the conversion date, the lowest trade price during the previous 15 trading days. The Company is amortizing the on-issuance discounts of $828,710 to interest expense using the straight-line method over the original terms of the loans. During 2020 the Company amortized $979,959 to interest expense. As of December 31, 2020, a discount of $409,650 remained. During 2020, we issued an aggregate of 1,363,463 As of December 31, 2020, future loan maturities are as follows: For the year ending December 31, 2021 1,305,005

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
DERIVATIVE LIABILITIES
NOTE 5 - DERIVATIVE LIABILITIES	NOTE 5 – DERIVATIVE LIABILITIES Derivative Liabilities In connection with convertible notes payable, the Company records derivative liabilities for the conversion feature. The derivative liabilities are valued on the date the convertible note payable become convertible and revalued at each reporting period. During the nine-months September $1,077,757 $0.0248 $0.0340 75.03% to $697,602, In August 2021, we completed the sale of 15% Original Issue Discount Senior Notes (“Bridge Notes”) in the aggregate principal amount of $4,456,176 to a group of institutional investors (the “Purchasers”). A portion of the proceeds were used to repay the principal, accrued interest, pre-payment fees and other premiums of all the outstanding convertible notes as well as all previously outstanding warrants with re-pricing and anti-dilutive features. The result was $0 in derivative liabilities as-of the period ended September 30,2021.	NOTE 5 – DERIVATIVE LIABILITIES Derivative Liabilities In connection with convertible notes payable and the related party management fee and patent liability, the Company records derivative liabilities for the conversion feature. In addition, the Company has warrants for which the exercise prices reset upon future events. These warrants are also considered to be derivative liabilities. The derivative liabilities are valued on the date the convertible note payable and the related party liabilities become convertible and revalued at each reporting period. The warrants are valued on the date of issuance and revalued at each reporting period. During the year ended December 31, 2020, the Company recorded initial derivative liabilities of $2,572,723 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of 0.40 $0.60 $1.70 $18.25, On December 31, 2020, the derivative liabilities were revalued at $38,741,832 resulting in a loss of $33,980,805 related to the change in fair market value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of $0.40 $6.70, $13.90, During the year ended December 31, 2019, the Company recorded initial derivative liabilities of $2,794,910 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $25.00 1,545, $30.00 $1,390, On December 31, 2019, the derivative liabilities were revalued at $6,847,877 resulting in a loss of $3,512,648 related to the change in fair market value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of $10.00 $295, $25.00, Future Potential Dilution Most of the Company’s convertible notes payable contain adjustable conversion terms with significant discounts to market. As of December 31, 2020, the Company’s convertible notes payable are potentially convertible into an aggregate of approximately 1.4 billion shares of common stock. In addition, due to the variable conversion prices on some of the Company’s convertible notes, the number of common shares issuable is dependent upon the traded price of the Company’s common stock.

WARRANTS

WARRANTS	9 Months Ended
	Sep. 30, 2021
WARRANTS
NOTE 6 - WARRANTS	NOTE 6 – WARRANTS From January 2021 through September 421,066 a non-convertible debt issuance and nine- September two 43,167 The fair value of each warrant is estimated using the Black-Scholes valuation model on the date of issuance and if needed at each period end. Assumptions used in calculating the fair value during the nine September Weighted Average Inputs Used Annual dividend yield $ - Expected life (years) 2.7 to 10.0 Risk-free interest rate 0.23% to 0.81 % Expected volatility 92.93% % Common stock price $ 11.5000 to $17.0000 Since the expected life of the warrants was greater than the Company’s historical stock information available, the Public Company determined the expected volatility based on price fluctuations of comparable public companies. The issuances, exercises and pricing re-sets during the nine September Outstanding at December 31, 2020 152,738 Issuances 441,255 Exercises (43,167 ) Anti-Dilution/Modification - Forfeitures/cancellations (69,475 ) Outstanding at September 481,351 Weighted Average Price at September $ 13.2809

STOCKHOLDERS DEFICIT

STOCKHOLDERS DEFICIT	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
STOCKHOLDERS DEFICIT
NOTE 7 - STOCKHOLDERS' DEFICIT	NOTE 7 – STOCKHOLDERS’ DEFICIT Series B Convertible Preferred Stock Equity Financing On February 11, 2021, the Board of Directors of the Corporation had authorized issuance of up to 350 shares of preferred stock, $0.001 par value per share, designated as Series B Convertible Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $1,200, subject to increase set forth in the Certificate of Designation. Dividends: Voting Rights: Liquidation: Conversion: Redemption: · 105% of the stated value if the redemption takes place within 90 days of issuance; · 110% of the stated value if the redemption takes place after 90 days and within 120 days of issuance · 120% of the stated value if the redemption takes place after 120 days and within 180 days of issuance In addition, the Series B Preferred Stock contain various redemption provisions for which are contingent upon future events including but not limited to having sufficient authorized shares, change in control, bankruptcy, etc. Upon a triggering event, the Company the redemption price is 125% of the stated value plus all unpaid dividends and liquidated damages. Most Favored Nation Provision. On February 12, 2021, pursuant to the terms noted above, the Company entered into a new preferred equity financing agreement with BHP Capital, LLC (“BHP”) in the amount of $350,000 for 350 shares of the newly-designated Series B Convertible Preferred Stock valued at $1,200 per share for which $326,600 in proceeds were received by the Company. In connection with the closing, the Company issued an additional 3,000 In August 2021, the preferred shares were redeemed at 120% of their stated value per the terms of their designations through the issuance of the bridge note with the same terms as the bridge note described in Note 4. Series C Convertible Preferred Stock Equity Financing On March 30, 2021, the Board of Directors of the Corporation had authorized issuance of up to 150 shares of preferred stock, $0.001 par value per share, designated as Series C Convertible Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $1,200, subject to increase set forth in the Certificate of Designation. Dividends: Voting Rights: Liquidation: Conversion: Redemption: · 105% of the stated value if the redemption takes place within 90 days of issuance; · 110% of the stated value if the redemption takes place after 90 days and within 120 days of issuance · 120% of the stated value if the redemption takes place after 120 days and within 180 days of issuance In addition, the Series C Preferred Stock contain various redemption provisions for which are contingent upon future events including but not limited to having sufficient authorized shares, change in control, bankruptcy, etc. Upon a triggering event, the Company the redemption price is 125% of the stated value plus all unpaid dividends and liquidated damages. Most Favored Nation Provision. On March 30, 2021, pursuant to the terms noted above, the Company entered into a new preferred equity financing agreement with Fourth Man, LLC (“FM”) in the amount of $150,000. The closing under the SPA consisted of 150 shares of Series C Convertible Preferred Stock, stated value $1,200 per share, issued to FM for a purchase price of $150,000, or $1,000 per share, for which $141,049 in proceeds were received by the Company. In connection with the closing, the Company issued an additional 642,857 shares of common stock as a service fee. The Company has accounted for the transaction with equity at the proceeds received was considered consideration for all securities issued. In August 2021, the preferred shares were redeemed at 120% of their stated value per the terms of their designations through the issuance of the bridge note with the same terms as the bridge note described in Note 4.	NOTE 7 – STOCKHOLDERS’ DEFICIT During 2019, the Company entered into convertible loan agreements with third parties that included 486 $295 $1,545. 1,188 1,062 10,089 Assumptions used in calculating the fair value of the warrants issued in 2019 were as follows: Range of Inputs Used Annual dividend yield $ - Expected life (years) 5.00 Risk-free interest rate 1.56 to 2.23 % Expected volatility 82.85% to 92.64.00 % Common stock price $ 295 to 760 During 2020, the Companygranted 3-year warrants to three board members to purchase an aggregate of 60,000 shares of common stock at a price of $0.004 and 8,214,286 to a contractor for services rendered at prices ranging from $2.00 $2.50. 291 69,063 152,745 Assumptions used in calculating the fair value of the warrants issued in 2020 were as follows: Range of Inputs Used Annual dividend yield $ - Expected life (years) 3.00 Risk-free interest rate 0.11% to 0.29 % Expected volatility 99.24% to 106.51 % Common stock price $ 1.45 to 2.50 Warrant activity for the years ended December 31, 2020 and 2019 consists of the following: Warrants Weighted Weighted Outstanding, December 31, 2018 1,894 $ 355.00 4.22 Issued 486 Exercises (1,188 ) Anti-Dilution Modifications 9,100 Forfeiture/Cancellations (203 ) - Outstanding, December 31, 2019 10,089 $ 45.00 3.08 Issued 83,262 Exercises - Anti-Dilution Modifications 59,394 - Forfeiture/Cancellations - Outstanding, December 31, 2020 152,745 $ 2.85 2.47 Vested, December 31, 2020 152,745 $ 2.85 2.47 See Note 5 for discussion regarding anti-dilution and modifications related to warrants accounted for as derivative liabilities. See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements. See Note 3 for discussion related to the issuance of common stock to a related party for cash.

STOCKBASED COMPENSATION

STOCKBASED COMPENSATION	12 Months Ended
	Dec. 31, 2020
STOCKBASED COMPENSATION
NOTE 8 - STOCK-BASED COMPENSATION	NOTE 6 – STOCK-BASED COMPENSATION The Company has reserved 27 Plan In July and September 2016, the Company granted 10-year options to two parties for accepting appointment to the Company’s scientific advisory board. Each award consisted of options to purchase up to 500 $87.50 Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies. There were no options issued during the years ended December 31, 2020 and 2019. Option activity for the years ended December 31, 2020 and 2019 consists of the following: Stock Options Weighted Average Exercise Price Weighted Average Life Remaining Outstanding, December 31, 2018 7 $ 13,125 7.65 Issued - - - Exercised - - - Expired - - - Outstanding, December 31, 2019 7 $ 13,125 6.65 Issued - - - Exercised - - - Expired - - - Outstanding, December 31, 2020 7 $ 13,125 5.64 Vested, December 31, 2020 5 $ 13,125 5.64 See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements. See Note 4 and 5 for discussion regarding warrants issued with a convertible note payable. From April through September 2020, we granted 23,262 $1.45 $3.50. . The fair value of each warrant award is estimated using the Black-Scholes valuation model. Assumptions used in calculating the fair value during the year ended December 31, 2020 were as follows: Weighted Annual dividend yield $ - Expected life (years) 3.0 Risk-free interest rate 0.11% to0.94 % Expected volatility 95.27% to 106.51 % Common stock price $ 1.45 to 9.50 See Note 7 for warrant rollforward.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2020
INCOME TAXES
NOTE 9 - INCOME TAXES	NOTE 8 – INCOME TAXES The provision for income tax expense consists of the following at December 31, 2020 and 2019: 2020 2019 Income tax provision attributable to: Federal $ (250,771 ) $ (272,800 ) State and local (69,671 ) (75,792 ) Valuation allowance 320,442 (348,592 ) Net provision for income tax $ - $ - Deferred tax assets consist of the following at December 31, 2020 and 2019: 2020 2019 Deferred tax asset attributable to: Net operating loss carryover $ 1,593,282 $ 1,347,378 Accrued management fees, related party 155,063 80,825 Valuation allowance (1,748,345 ) (1,427,903 ) Net deferred tax asset $ - $ - The primary difference between the statutory federal rate and the Company’s effective tax rate for the years ended December 31, 2020 and 2019 was due to the 100% valuation allowance. The following is a reconciliation of the statutory federal rate and the Company’s effective tax rate for the year ended December 31, 2020 and 2019: 2020 2019 Tax at federal statutory rate 21.0 % 21.0 % State, net of federal benefit 0.2 % 0.9 % Change in temporary differences (0.0 )% 0.0 )% Permanent differences (20.2 ) (17.9 )% Valuation allowance (0.9 )% (4.1 )% Provision for taxes - As of December 31, 2020, the Company had federal and state gross net operating loss carryforwards of approximately $6.5 million. The federal and state net operating losses and tax credits expire in years beginning in 2036. Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. To date, the Company hasn’t experienced “ownership changes” under section 382 of the Code and comparable state tax laws. As of December 31, 2020, the Company estimates that none of the federal and state net operating losses will be limited under Section 382 of the Code. As of December 31, 2020, and 2019, the Company maintained a full valuation allowance on its net deferred tax assets. The valuation allowance was determined in accordance with the provisions of ASC 740, Accounting for Income Taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. The Company’s history of cumulative losses, along with expected future U.S. losses required that a full valuation allowance be recorded against all net deferred tax assets. The Company intends to maintain a full valuation allowance on net deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The applicable federal and state rates used in calculating the deferred tax provision was 21.0% and 8.9%, respectively. The Company files income tax returns in the U.S. and Arizona. All years presented remain subject to examination for U.S. federal and state purposes. The Company is not currently under examination in federal or state jurisdictions.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
SUBSEQUENT EVENTS
NOTE 10 - SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS In accordance with ASC 855, management reviewed all material events through November 15, In November, 2021, following the approval of the Company’s Board of Directors and holders of a majority the Company’s voting stock, the Company filed an amendment to its Articles of Incorporation increasing the Company’s authorized shares of Common Stock to 25 billion from 6 billion. Thereafter, on November 10, 2021, following the approval of the Board of Directors of the Company, the Company effected a 1-for-500 reverse split of the both the Company’s authorized and outstanding shares of Common Stock, by filing a Certificate of Change with the Nevada Secretary of State under Section 78.209 of the Nevada Revised Statutes. Following the stock split, the Company’s authorized common stock was reduced to 50,000,000 shares, and the Company had outstanding approximately 2,452,348 shares of Common Stock. No fractional shares will be issued, and no cash or other consideration will be paid, in connection with the reverse stock split. Instead, the Company will issue one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the reverse stock split. All share references have been restated for this reverse split to the earliest period presented.	NOTE 9 – SUBSEQUENT EVENTS On January 8, 2021 shares of common stock were issued to CMH in satisfaction of a $50,000 payment owed to CMH under the Patent Purchase Agreement, dated May 17, 2017, as amended on November 14, 2017, between us, our wholly-owned subsidiary StemSpine, LLC, and CMH. Pursuant to the Patent Agreement, the number of shares issued was calculated based on a 30% discount to the closing trading price of the common stock of $.0016 on December 9, 2020. In February 2020, we completed the sale of two 10% Original Issue Discount Senior Convertible Notes to two institutional investors pursuant to a Securities Purchase Agreement between the Company and the investors. The transactions were effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder. Pursuant to the Purchase Agreements, for an aggregate purchase price of $144,500, the Investors purchased the notes in the aggregate principal amount of $157.150. The notes mature in February, 2021, bear interest at a rate of 8% per annum, and are convertible into shares of the Company’s common stock at a conversion prices ranging from to 60% to 61% of the average of the two lowest traded price of the Company’s common stock during the 15 trading days preceding the applicable conversion date. On February 12, 2021, we completed the sale to an institutional investor 350,000 shares of the our newly designated Series B Preferred Stock pursuant to a Securities Purchase Agreement between the Company and the Purchaser for an aggregate purchase price of $350,000. In addition, pursuant to the Purchase Agreement, we issued the Purchaser 3,000 Each share of Series B Preferred Stock has a Stated Value of $1,200.00 and is convertible into Common Stock at a conversion price equal to $25. $17.50 The Series B Preferred Stock (i) carries a quarterly dividend at the rate of 10% per annum, payable in cash or additional shares of Series B Preferred Stock, at the Company’s option, and (ii) may be redeemed by us, at its option, upon the payment of an amount equal to (a) $1,200 per share of Series B Preferred Stock, plus all accrued dividends thereon and any unpaid fees or liquidated damages then due with respect to the Series B Preferred Stock pursuant to the Certificate of Designation, multiplied by (b) a premium ranging from 5% if the redemption occurs within 90 days following the issuance of the Series B Preferred Stock, to 20% if the redemption occurs between 120 and 180 days following the issuance of the Series B Preferred Stock. On March 11, 2020, following the approval of the Board of Directors of the Company filed a Certificate of Amendment to the Certificate of Designation of the Company’s Series A Preferred Stock with the Secretary of State of the State of Nevada (the “Certificate of Amendment”). The Certificate of Amendment increased the voting power of the Series A Preferred Stock to 10,00 votes per share from 30 votes per share. The Company has 3,000,000 shares of Series A Preferred Stock outstanding, all of which are held by Timothy Warbington. From January 1, 2021 through March 17, 2021, we issued 623,404 During January and February, 2021 we issued 20,111 23,167 In November, 2021, following the approval of the Company’s Board of Directors and holders of a majority the Company’s voting stock, the Company filed an amendment to its Articles of Incorporation increasing the Company’s authorized shares of Common Stock to 25 billion from 6 billion. Thereafter, on November 10, 2021, following the approval of the Board of Directors of the Company, the Company effected a 1-for-500 reverse split of the both the Company’s authorized and outstanding shares of Common Stock, by filing a Certificate of Change with the Nevada Secretary of State under Section 78.209 of the Nevada Revised Statutes. Following the stock split, the Company’s authorized common stock was reduced to 50,000,000 shares, and the Company had outstanding approximately 2,452,348 shares of Common Stock. No fractional shares will be issued, and no cash or other consideration will be paid, in connection with the reverse stock split. Instead, the Company will issue one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the reverse stock split. All share references have been restated for this reverse split to the earliest period presented.

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization	Organization – Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments. Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AmnioStem LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AmnioStem LLC have commenced commercial activities. We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem ® ® ® ® In addition to our CaverStem ® ® ® ® In 2020, through our ImmCelz Inc. subsidiary, we began exploring the development of treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties that may be suitable for the treatment of stroke victims, among other indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.	Organization CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing amniotic stem cells, and the treatment of neurologic disorders and lower back pain using various types of stem cells through its AmnioStem LLC, StemSpine, LLC, and ImmCelz, Inc. subsidiaries. However, neither AmnioStem LLC, StemSpine, Inc. nor ImmCelz, Inc. have commenced commercial activities.
Risks and Uncertainties	Risks and Uncertainties	Risks and Uncertainties On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time consuming and could delay launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.
Use of Estimates	Use of Estimates	Use of Estimates
Basis of Presentation	Basis of Presentation September September	Basis of Presentation U.S. GAAP
Going Concern	Going Concern nine-month September $1,054,446 $917,327 In August were and is being used to fund operations - . If the Company raises additional funds through offerings of shares of common stock or other securities, such offerings would cause dilution of current stockholders’ percentage ownership in the Company, which could be substantial. Future offerings could also have a material and adverse effect on the price of the Company’s common stock. On September 28, 2021, the Company filed a Registration Statement on Form S-1 with the Securities and Exchange Commission to raise capital through the offer and sale of units consisting of shares of common stock and warrants to purchase additional shares of common stock in a firm commitment underwriting to be conducted by Roth Capital Partners. However, there can be no assurance that the Company will be successful in completing the offering. The securities to be sold in the offering may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective	Going Concern
Concentration Risks		Concentration Risks
Cash Equivalents		Cash Equivalents
Fair Value of Financial Instruments	Fair Value of Financial Instruments When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September Notes Warrants Total Derivative liability at December 31, 2020 $ 37,343,835 $ 1,397,997 $ 38,741,832 Addition of new conversion option derivatives 1,077,757 - 1,077,757 Extinguishment/modification (726,998 ) (346 ) (727,344 ) Conversion of note derivatives (10,494,316 ) (1,869,768 ) (12,364,084 ) Change in fair value (27,200,278 ) 472,117 (26,728,161 ) Derivative liability at September $ - $ - $ -	Fair Value of Financial Instrument Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: Notes Warrants Total Derivative liability at December 31, 2019 $ 6,659,055 $ 188,822 $ 6,847,877 Addition of new conversion option derivatives 2,572,723 - 2,572,723 Extinguishment/modification - - - Conversion of note derivatives (2,795,340 ) - (2,795,340 ) Change in fair value 30,907,397 1,209,175 32,116,572 Derivative liability at December 31, 2020 $ 37,343,835 $ 1,397,997 $ 38,741,832
Intangible Assets		Intangible Assets
Impairment		Impairment
Derivative Liabilities		Derivative Liabilities As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2020 and 2019, as disclosed in Notes 4 and 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification), and the change in fair value is recorded on our consolidated statement of operations.
Revenue	Revenue	Revenue The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer. Payments received for which the earnings process is not yet complete are deferred. As of December 31, 2020, the Company had deferred revenue of $32,000 included within current liabilities in the accompanying consolidated balance sheet.
Research and Development		Research and Development 1. Erectile Dysfunction Technology based upon the use of stem cells. These costs, which consist primarily of monies paid for clinical trial expenses, materials and supplies and compensation costs amounted to $0 for the year ended December 31, 2020. There were $0 in research costs for the period ended December 31, 2019; 2. Amniotic Fluid-based Stem Cells. Pre-clinical research costs, which consist primarily of monies paid for laboratory space, materials and supplies amounted to $0 for the year ended December 31, 2020. There were $0 in research costs for the period ended December 31, 2019.
Stock-Based Compensation		Stock-Based Compensation
Income Taxes		Income Taxes The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The Company will recognize interest and penalties related to unrecognized tax benefits in the income tax provision in the accompanying statement of operations. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income taxes paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of relevant risks, facts and circumstances existing at that time. To the extent that the assessment of such tax positions change, the change in estimate is recorded in the period in which the determination is made.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share – The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the nine-months September For the Three Months Ended September 30, 2020 For the Nine Months Ended September 30, 2021 For the Nine Months Ended September 30, 2020 Weighted average common shares outstanding used in calculating basic earnings per share 684,983 2,313,005 369,423 Effect of Series B and C preferred stock - - - Effect of warrants 47,784 50,140 56,313 Effect of convertible notes payable 1,579,107 - 1,307,727 Effect of convertible related party management fee and patent liabilities 413,896 - 413,896 Weighted average common shares outstanding used in calculating diluted earnings per share 2,452,076 2,363,145 2,138,913 Net income as reported $ 394,851 $ 23,087,241 $ 2,294,768 Add - Interest on convertible notes payable 28,228 - 105,338 Net income available to common stockholders $ 423,079 $ 23,087,241 $ 2,400,106 Diluted income per Share $ 0.16 $ 9.77 $ 1.12 The Company excluded 7 18 nine-months September During the three-month period ended September 7 481,351 September The Company excluded 7options and 17,842 warrants from the computation of diluted net income per share for the three-months ended September 30, 2020 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period. The Company excluded 7 options and 413 warrants from the computation of diluted net income per share for the nine-months ended September 30, 2020 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period. On November 10, 2021, we effected a 1-for-500 reverse split of our authorized and issued and outstanding shares of common stock. All share references have been restated for this reverse split to the earliest period presented. As a result of the split, the authorized shares of the Company’s common stock decreased to 50,000,000 shares.	Basic and Diluted Loss Per Share 7 152,738 7 10,089
Recent Accounting Pronouncements	Recent Accounting Pronouncements	Recent Accounting Pronouncements

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Summary of outstanding securities	For the Three Months Ended September 30, 2020 For the Nine Months Ended September 30, 2021 For the Nine Months Ended September 30, 2020 Weighted average common shares outstanding used in calculating basic earnings per share 684,983 2,313,005 369,423 Effect of Series B and C preferred stock - - - Effect of warrants 47,784 50,140 56,313 Effect of convertible notes payable 1,579,107 - 1,307,727 Effect of convertible related party management fee and patent liabilities 413,896 - 413,896 Weighted average common shares outstanding used in calculating diluted earnings per share 2,452,076 2,363,145 2,138,913 Net income as reported $ 394,851 $ 23,087,241 $ 2,294,768 Add - Interest on convertible notes payable 28,228 - 105,338 Net income available to common stockholders $ 423,079 $ 23,087,241 $ 2,400,106 Diluted income per Share $ 0.16 $ 9.77 $ 1.12
Schedule of licensing agreements		Assets Accumulated Amortization Balances at December 31, 2019 $ 510,000 $ (73,445 ) Addition of new assets 250,000 - Amortization - (66,792 ) Balances at December 31, 2020 $ 760,000 $ (140,237 )
Schedule of future expected amortization		For the year ended December 31, 2021 93,327 2022 93,327 2023 93,327 2024 93,327 2025 93,327 Thereafter 152,835 Total $ 619,470
Schedule of Fair Value	Notes Warrants Total Derivative liability at December 31, 2020 $ 37,343,835 $ 1,397,997 $ 38,741,832 Addition of new conversion option derivatives 1,077,757 - 1,077,757 Extinguishment/modification (726,998 ) (346 ) (727,344 ) Conversion of note derivatives (10,494,316 ) (1,869,768 ) (12,364,084 ) Change in fair value (27,200,278 ) 472,117 (26,728,161 ) Derivative liability at September $ - $ - $ -	Notes Warrants Total Derivative liability at December 31, 2019 $ 6,659,055 $ 188,822 $ 6,847,877 Addition of new conversion option derivatives 2,572,723 - 2,572,723 Extinguishment/modification - - - Conversion of note derivatives (2,795,340 ) - (2,795,340 ) Change in fair value 30,907,397 1,209,175 32,116,572 Derivative liability at December 31, 2020 $ 37,343,835 $ 1,397,997 $ 38,741,832

LICENSING AGREEMENTS (Tables)

LICENSING AGREEMENTS (Tables)	12 Months Ended
	Dec. 31, 2020
LICENSING AGREEMENTS
Schedule of licensing agreements
Schedule of future expected amortization

DEBT (Tables)

DEBT (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
DEBT
Schedule of future loan maturities	For the year ended December 31, 2021 0 2022 5,146,176 Total $ 5,146,176	For the year ending December 31, 2021 1,305,005

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2021
WARRANTS
Schedule of Warrants	Weighted Average Inputs Used Annual dividend yield $ - Expected life (years) 2.7 to 10.0 Risk-free interest rate 0.23% to 0.81 % Expected volatility 92.93% % Common stock price $ 11.5000 to $17.0000
Schedule of fair value of warrants	Outstanding at December 31, 2020 152,738 Issuances 441,255 Exercises (43,167 ) Anti-Dilution/Modification - Forfeitures/cancellations (69,475 ) Outstanding at September 481,351 Weighted Average Price at September $ 13.2809

STOCKBASED COMPENSATION (Tables

STOCKBASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2020
STOCKBASED COMPENSATION
Schedule of Warrant	Stock Options Weighted Average Exercise Price Weighted Average Life Remaining Outstanding, December 31, 2018 7 $ 13,125 7.65 Issued - - - Exercised - - - Expired - - - Outstanding, December 31, 2019 7 $ 13,125 6.65 Issued - - - Exercised - - - Expired - - - Outstanding, December 31, 2020 7 $ 13,125 5.64 Vested, December 31, 2020 5 $ 13,125 5.64
Schedule of fair value of warrant	Weighted Annual dividend yield $ - Expected life (years) 3.0 Risk-free interest rate 0.11% to0.94 % Expected volatility 95.27% to 106.51 % Common stock price $ 1.45 to 9.50

STOCKHOLDERS DEFICIT (Tables)

STOCKHOLDERS DEFICIT (Tables)	12 Months Ended
	Dec. 31, 2020
STOCKHOLDERS DEFICIT
Schedule of Stockholders Deficit	Range of Inputs Used Annual dividend yield $ - Expected life (years) 5.00 Risk-free interest rate 1.56 to 2.23 % Expected volatility 82.85% to 92.64.00 % Common stock price $ 295 to 760
Schedule of warrant activity	Range of Inputs Used Annual dividend yield $ - Expected life (years) 3.00 Risk-free interest rate 0.11% to 0.29 % Expected volatility 99.24% to 106.51 % Common stock price $ 1.45 to 2.50 Warrants Weighted Weighted Outstanding, December 31, 2018 1,894 $ 355.00 4.22 Issued 486 Exercises (1,188 ) Anti-Dilution Modifications 9,100 Forfeiture/Cancellations (203 ) - Outstanding, December 31, 2019 10,089 $ 45.00 3.08 Issued 83,262 Exercises - Anti-Dilution Modifications 59,394 - Forfeiture/Cancellations - Outstanding, December 31, 2020 152,745 $ 2.85 2.47 Vested, December 31, 2020 152,745 $ 2.85 2.47

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2020
INCOME TAXES
Schedule of income taxes	2020 2019 Income tax provision attributable to: Federal $ (250,771 ) $ (272,800 ) State and local (69,671 ) (75,792 ) Valuation allowance 320,442 (348,592 ) Net provision for income tax $ - $ -
Schedule of deferred tax assets	2020 2019 Deferred tax asset attributable to: Net operating loss carryover $ 1,593,282 $ 1,347,378 Accrued management fees, related party 155,063 80,825 Valuation allowance (1,748,345 ) (1,427,903 ) Net deferred tax asset $ - $ -
Schedule of effective tax rate	2020 2019 Tax at federal statutory rate 21.0 % 21.0 % State, net of federal benefit 0.2 % 0.9 % Change in temporary differences (0.0 )% 0.0 )% Permanent differences (20.2 ) (17.9 )% Valuation allowance (0.9 )% (4.1 )% Provision for taxes -

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Derivative liability, beginning	$ 38,741,832	$ 6,847,877
Addition of new conversion option derivatives	1,077,757	2,572,723
Extinguishment/modification	(727,344)	0
Conversion of note derivatives	(12,364,084)	(2,795,340)
Change in fair value	(26,728,161)	32,116,572
Derivative liability, ending	0	38,741,832
Warrants [Member]
Derivative liability, beginning	1,397,997	188,822
Addition of new conversion option derivatives	0	0
Extinguishment/modification	(346)	0
Conversion of note derivatives	(1,869,768)	0
Change in fair value	472,117	1,209,175
Derivative liability, ending	0	1,397,997
Notes [Member]
Derivative liability, beginning	37,343,835	6,659,055
Addition of new conversion option derivatives	1,077,757	2,572,723
Extinguishment/modification	(726,998)	0
Conversion of note derivatives	(10,494,316)	(2,795,340)
Change in fair value	(27,200,278)	30,907,397
Derivative liability, ending	$ 0	$ 37,343,835

ORGANIZATION AND SUMMARY OF S_5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Weighted average common shares outstanding used in calculating basic earnings per share	2,452,076	684,983	2,313,005	369,423
Effect of warrants		47,784	50,140	56,313
Effect of convertible notes payable		1,579,107		1,307,727
Effect of convertible related party management fee and patent liabilities		413,896		413,896
Weighted average common shares outstanding used in calculating diluted earnings per share		2,452,076	2,363,145	2,138,913
Net income as reported		$ 394,851	$ 23,087,241	$ 2,294,768
Add - Interest on convertible notes payable		28,228	0	105,338
Net income available to common stockholders		$ 423,079	$ 23,087,241	$ 2,400,106
Diluted income per Share		$ 0.16	$ 9.77	$ 1.12

ORGANIZATION AND SUMMARY OF S_6

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Nov. 10, 2021	Feb. 29, 2016	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Nov. 30, 2021
Working capital deficit			$ (917,327)		$ (917,327)		$ (40,422,773)
Intellectual property		$ 8,372,797
Net loss			(1,843,596)	$ 394,851	23,087,241	$ 2,294,768	(36,325,230)	$ (8,483,673)
Concentration of risk							250,000
Notes receivables			$ 3,700,000		3,700,000
Compensation costs							$ 0
Debt conversion, converted instrument, shares issued				699,863,854			14,000,000,000
Deferred revenue							$ 32,000
Cash used in operating activity					$ (1,054,446)	$ (491,542)	$ (434,556)	$ (1,213,093)
Common stock authorized shares			6,000,000,000		6,000,000,000		12,000,000,000	1,200,000,000
Warrants [Member]
Anti-dilutive securities excluded from computation of earning per share			481,351	17,842	18	413
Warrants to purchase common stock outstanding							152,738	10,089
Options [Member]
Anti-dilutive securities excluded from computation of earning per share			7	7	7	7
Options to purchase common stock outstanding							7	7
Subsequent Event [Member]
Description of reverse stock split	1-for-500 reverse split of the both the Company’s authorized and outstanding shares of Common Stock
Common stock authorized shares	50,000,000								50,000,000

LICENSING AGREEMENTS (Details)

LICENSING AGREEMENTS (Details)	Dec. 31, 2020USD ($)
LICENSING AGREEMENTS
2021	$ 93,327
2022	93,327
2023	93,327
2024	93,327
2025	93,327
Thereafter	152,835
Total	$ 619,470

LICENSING AGREEMENTS (Details 1

LICENSING AGREEMENTS (Details 1)	12 Months Ended
	Dec. 31, 2020USD ($)
Assets
Beginning Balance	$ 510,000
Addition of new assets	250,000
Amortization	0
Ending Balance	760,000
Accumulated Amortization
Accumulated Amortization, Beginning Balance	(73,445)
Addition of new assets	0
Amortization	(66,792)
Accumulated Amortization, Ending Balance	$ (140,237)

LICENSING AGREEMENTS (Details N

LICENSING AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 28, 2020	Nov. 30, 2019	May 17, 2017	Feb. 02, 2016	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Patent cost									$ 25,000
Carrying value									$ 250,000
Stock Issued During Period, Shares, Purchase of Assets				862
Stock Issued During Period, Value, Purchase of Assets				$ 100,000
License fees	$ 250,000						$ 250,000
License agreement description	which can also be paid in CELZ stock at a discount of 25% of the closing price of $1.85 which is based on the date of this agreement
Continuing royalty description							Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelzTM. during such calendar quarter (the “Continuing Royalty”)		Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”)
Patent cost					$ 550,700		$ 550,700		$ 619,763	$ 436,555
Amortization of Intangible Assets					6,250	$ 0	18,750	$ 0	66,792	26,950
Common stock issued for related party patent and management liabilities, amount							50,000
Stemspine LLC [Member]
Carrying value									248,254
Amortization of Intangible Assets					2,493		$ 7,479		46,000	5,806
Amortization expense									45,940	5,806
Royalty payment percentage			5.00%				5.00%
Non-royalty sublease income percentage.			50.00%				50.00%
Patents [Member]
Patent cost					43,481		$ 43,481		$ 50,960
Amortization of Intangible Assets					2,493		$ 7,479			5,806
Expiration period of finite-lived intangible assets							2026		2036
Expected amount of amortization									$ 9,972
Patents [Member] | Creative Medical Health Inc [Member]
Patent cost					213,799		$ 213,799		248,254
Amortization of Intangible Assets					$ 293	293	879	882	$ 50,960	9,972
Expiration period of finite-lived intangible assets									2027
Expected amount of amortization									$ 46,000
Initial payment		$ 300,000					$ 100,000
Common stock issued for related party patent and management liabilities, shares							89,286
Common stock issued for related party patent and management liabilities, amount							$ 50,000
Percentage of discount on the basis of recent trading price			30.00%		30.00%		30.00%
Patents [Member] | Creative Medical Health Inc [Member] | Scenario One [Member]
Payments upon signing agreement with university for the initiation of an IRB clinical trial			$ 100,000				$ 100,000
Payments upon completion of the IRB clinical trial			200,000				200,000
Payments in the event of commercialization of technology			300,000				300,000
Patents [Member] | Creative Medical Health Inc [Member] | Scenario Two [Member]
Payments upon filing an IND with the FDA			100,000				100,000
Payments upon dosing of the first patient in a Phase 1-2 clinical trial			200,000				200,000
Payments upon dosing of the first patient in Phase 3 clinical trial			$ 400,000				400,000
Patents [Member] | Stemspine LLC [Member]
Carrying value									10,000
Patent cost					$ 57,500		57,500		65,000
Amortization of Intangible Assets					2,500		$ 7,500		$ 10,000	10,000
Expiration period of finite-lived intangible assets									2027
Expected amount of amortization									$ 10,000
Patent License Agreement [Member]
Patent cost									$ 25,000
Amortization period							10 years		10 years
Carrying value of patent					231,250		$ 231,250		$ 250,000
Expiration period of finite-lived intangible assets									2030
Multipotent Amniotic Fetal Stem Cells License Agreement [Member] | Patents [Member]
Carrying value									$ 5,256
Patent cost					4,670		4,670		5,549
Amortization of Intangible Assets					$ 11,485	$ 11,485	34,455	$ 34,455	$ 1,172	$ 1,172
Expiration period of finite-lived intangible assets									2026
Expected amount of amortization							$ 1,172		$ 1,172
Initial payment									$ 100,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)

Dec. 12, 2019

Apr. 11, 2018

May 04, 2017

Aug. 12, 2016

Sep. 15, 2021

Jun. 21, 2021

May 28, 2021

Dec. 31, 2018

Jul. 31, 2018

Apr. 30, 2018

Nov. 17, 2017

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2016

Description of monthly reimbursment amount of management fees

The agreement originally provided for a monthly reimbursement in the amount of $35,000, which amount was increased to $45,000 effective January 1, 2019

Debt Conversion, Converted Instrument, Shares Issued

699,863,854

14,000,000,000

Proceeds from Related Party Debt

$ 226,500

Reimbursement of management fees

$ 100,000

Proceeds from Lines of Credit

705,405

$ 0

Creative Medical Health [Member]

Debt Conversion, Converted Instrument, Shares Issued

19,711

Expense

$ 112,500

$ 135,000

Reimbursement of management fees

$ 45,000

$ 35,000

Number of Trading days

20 years

20 years

Management and consultant service

$ 35,000

Agreement Notice period

30 years

Debt Conversion, Original Debt, Amount

$ 136,003

Percentage of Common Stock, Discount on Shares at the market price

30.00%

Amounts due under the arrangement

$ 18,782

$ 82

Interest Payable, Current

0

Long-term Purchase Commitment, Amount

$ 100,000

$ 40,000

50,000

Cash payment

$ 50,000

$ 300,000

$ 300,000

Issuance of shares of common stock

667

84,656

133

Dr. Amit Patel

Proceeds from Related Party Debt

$ 2,000

$ 150,000

Mr. Timothy Warbington

Proceeds from Related Party Debt

$ 2,000

$ 50,000

Creative Medical Health [Member] | February Note [Member]

Interest Payable, Current

$ 4,050

Line of Credit Facility, Initiation Date

Feb. 2, 2016

Proceeds from Lines of Credit

$ 50,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 50,000

$ 50,000

Line of Credit Facility, Expiration Date

Apr. 30, 2018

Line of Credit Facility, Interest Rate During Period

8.00%

Creative Medical Health [Member] | May Note One [Member]

Interest Payable, Current

$ 4,050

Line of Credit Facility, Initiation Date

Jul. 31, 2017

May 1, 2016

Proceeds from Lines of Credit

$ 50,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 50,000

$ 50,000

$ 50,000

Line of Credit Facility, Expiration Date

Jul. 31, 2018

Apr. 30, 2018

Jul. 31, 2018

Line of Credit Facility, Interest Rate During Period

8.00%

Creative Medical Health [Member] | May Note Two [Member]

Line of Credit Facility, Initiation Date

May 18, 2016

Proceeds from Lines of Credit

$ 25,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 25,000

Line of Credit Facility, Expiration Date

May 18, 2018

DEBT (Details)

DEBT (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
For the year ended December 31
2021	$ 0	$ 1,305,005
2022	5,146,176
Total	$ 5,146,176

DEBT (Details Narrative)

DEBT (Details Narrative)	Aug. 11, 2021USD ($)	Aug. 12, 2016USD ($)	Jun. 21, 2021USD ($)	May 28, 2021USD ($)	Feb. 29, 2020	Sep. 30, 2021USD ($)integer$ / sharesshares	Sep. 30, 2020USD ($)shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)integershares
Represent the amount of reimbursement of management fees, monthly			$ 100,000
Remaining discount, amount						$ 0		$ 409,650
Pre-payment premiums associated with the extinguishment									$ 41,699
Amortizing on issuance discount to interest expense						$ 1,755,104	$ 804,898	$ 828,710
Extinguishment recorded							$ 23,000		$ 313,111
Number of shares issued upon conversion of debt | shares						789,727	777,865	1,363,463	23,746
Debt conversaion,Converrted instrument shares issued, shares | shares						37,870
Debt conversion, amount						$ 1,383,331	$ 1,033,418	$ 1,366,705	$ 1,501,275
Common stock issued for cashless warrant exercise (In Shares) | shares						43,167			1,062
Warrants exercises									$ 0
Proceeds from Convertible Debt						$ 3,887,750	0	710,920	1,302,795
Debt Instrument, Interest Rate During Period					8.00%
Proceeds from related party advances						226,500
Original issue discount						$ 1,755,104	$ 804,898	979,960	1,723,451
Bridge Notes [Member]
Principal amount	$ 690,000
Interest expense	$ 758,426
Term of warrant						5 years
Maturity date	Feb. 11, 2022
Purchase shares of common stock | shares						363,046
Initial exercise price per share | $ / shares						$ 14.175
Roth Capital Partners [Member]
Purchase shares of common stock | shares						20,189
Placement agent fee						$ 312,750
Institutional Investors [Member]
Principal amount	$ 4,456,176
Original sale discount percentage	15.00%
Convertible Notes Payable [Member]
Proceeds from Convertible Debt								$ 710,920	$ 1,302,795
Debt Instrument, Interest Rate During Period								8.00%	8.00%
Amortization of Debt Issuance Costs									$ 1,613,226
Convertible notes issued								$ 831,140	$ 1,572,400
Debt instrument descriptions								The notes are convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices of the Company’s common stock during the previous 15 trading days preceding the conversion date, the lowest trade price during the previous 15 trading days	The notes were convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 66% of the average of the two lowest traded prices of the Company’s common stock during the previous 15 trading days preceding the conversion date, the lowest trade price during the previous 20 trading days, or the volume weighted average price over the prior 15 trading days
Original issue discount									$ 1,194,357
Cancellation of common stock purchase | shares									21,533
Convertible Notes Payable [Member] | Maximum [Member]
Debt Instrument, Interest Rate During Period									11.00%
Debt Instrument, Convertible, Conversion Percentage								60.00%	66.00%
Convertible Notes Payable [Member] | Minimum [Member]
Debt Instrument, Interest Rate During Period									2.00%
Debt Instrument, Convertible, Conversion Percentage								71.00%	60.00%
Convertible Notes Payable [Member] | Accredited investors [Member]
Represent the amount of reimbursement of management fees, monthly			$ 105,000
Proceeds from Convertible Debt						$ 435,040
Debt Instrument, Interest Rate During Period						8.00%
Amortization of Debt Issuance Costs						$ 443,905			$ 1,613,226
Convertible notes issued						$ 498,800
Debt Instrument, Convertible, Threshold Consecutive Trading Days | integer						15
Percentage of Common Stock, Discount on Shares at the market price.			10.00%
Promissory Notes [Member]
Convertible notes issued									$ 100,000
Debt Instrument, Convertible, Threshold Consecutive Trading Days | integer									15
Debt Instrument, Unamortized Discount									$ 374,124
Promissory Notes [Member] | Maximum [Member]
Debt Instrument, Interest Rate During Period									11.00%
Promissory Notes [Member] | Minimum [Member]
Debt Instrument, Interest Rate During Period									8.00%
Mr. Timothy Warbington
Proceeds from related party advances		$ 2,000		$ 50,000
Interest rate, related party debt				5
Dr. Amit Patel
Proceeds from related party advances		$ 2,000		$ 150,000
Interest rate, related party debt				5

DERIVATIVE LIABILITIES (Details

DERIVATIVE LIABILITIES (Details Narrative) - USD ($)	Aug. 11, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Expected dividend yield			$ 0
Expected term			1 year
Derivative Liability		$ 1,077,757		$ 6,847,877
Initial Derivative Liability			$ 2,572,723	2,794,910
Derivative, Gain (Loss) on Derivatives, Net			33,980,805	3,512,648
Convertible debt			1,864,233	1,215,985
Derivative liabilities exceeded the face values		$ 697,602
Debt Conversion, Converted Instrument, Shares Issued | shares		37,000,000
Debt Conversion, Converted Instruments, Shares Issued		2,251,446
Institutional Investors [Member]
Principal amount	$ 4,456,176
Original sale discount percentage	15.00%
Initial Valuation [Member]
Expected term		1 year
Expected volatility rate		98.14%
Expected dividend yield		0
Risk free interest		0.10%
Revaluation [Member]
Derivative Liability		$ 2,275,578	38,741,832	6,847,877
Derivative, Gain (Loss) on Derivatives, Net			$ 33,980,805	$ 3,512,648
Minimum [Member]
Shares Price			$ 1.70	$ 30
Minimum [Member] | Employee Stock Option [Member]
Expected volatility rate			98.14%	87.61%
Risk free interest			0.16%	1.56%
Fair Value Assumptions, Expected Term			6 months	6 months
Minimum [Member] | Measurement Input Exercise Price [Member]
Derivative Liability, Measurement Input Ratio			$ 0.40	$ 0.05
Minimum [Member] | Measurement Input Expected Term [Member]
Derivative Liability, Measurement Input Ratio			1	1
Minimum [Member] | Measurement Input Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input Ratio			$ 0.16	1.56
Minimum [Member] | Initial Valuation [Member]
Expected volatility rate		98.81%
Stock price		0.0248
Stock price on the date of grant shares		$ 0.0340
Exercise price		0.0106
Minimum [Member] | Black-Scholes option pricing model [Member]
Expected volatility rate			103.79%
Stock price on the date of grant shares			$ 1.70
Minimum [Member] | Revaluation [Member] | Measurement Input Exercise Price [Member]
Derivative Liability, Measurement Input Ratio			0.40	10
Minimum [Member] | Revaluation [Member] | Measurement Input Expected Term [Member]
Derivative Liability, Measurement Input Ratio			13.90	25
Maximum [Member]
Risk free interest		0.46%
Shares Price			$ 18.25	$ 139,078
Maximum [Member] | Employee Stock Option [Member]
Expected volatility rate			100.94%	103.96%
Risk free interest			1.62%	2.55%
Fair Value Assumptions, Expected Term			3 years 6 months 25 days	4 years 6 months 29 days
Maximum [Member] | Measurement Input Exercise Price [Member]
Derivative Liability, Measurement Input Ratio			$ 0.60	$ 3.09
Maximum [Member] | Initial Valuation [Member]
Expected volatility rate		75.03%
Stock price		0.0310
Stock price on the date of grant shares		$ 0.0806
Exercise price		0.0248
Risk free interest		0.70%
Maximum [Member] | Black-Scholes option pricing model [Member]
Expected volatility rate			131.89%
Stock price on the date of grant shares			$ 18.25
Maximum [Member] | Revaluation [Member] | Measurement Input Exercise Price [Member]
Derivative Liability, Measurement Input Ratio			$ 6.70	$ 295

WARRANTS (Details)

WARRANTS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Annual dividend yield		$ 0
Warrants [Member]
Annual dividend yield	$ 0
Expected life (years)		3 years	5 years
Warrants [Member] | Maximum [Member]
Expected life (years)	10 years
Risk-free interest rate	0.81%	0.29%	2.23%
Expected volatility	98.81%	106.51%	92.64%
Common stock price	$ 17	$ 9.50
Warrants [Member] | Minimum [Member]
Expected life (years)	2 years 8 months 12 days
Risk-free interest rate	0.23%	0.11%
Expected volatility	92.93%	95.27%
Common stock price	$ 11.5000	$ 1.45

WARRANTS (Details 1)

WARRANTS (Details 1) - Warrants [Member] - $ / shares	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Outstanding, beginning period	152,738
Issuances	441,255
Exercises	(43,167)
Forfeitures/cancellations	(69,475)
Outstanding, ending period	481,351
Weighted Average Price	$ 13.2809	$ 2.85	$ 45	$ 355

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - Scientific Advisory Board And Employee [Member]	9 Months Ended
	Sep. 30, 2021shares
Warrants issued	421,066
Individuals exercised warrants	43,167

STOCKHOLDERS DEFICIT (Details)

STOCKHOLDERS DEFICIT (Details) - Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Annual dividend yield		0.00%	0.00%
Expected life (years)		3 years	5 years
Maximum [Member]
Expected life (years)	10 years
Risk-free interest rate	0.81%	0.29%	2.23%
Expected volatility	98.81%	106.51%	92.64%
Common stock price		$ 1.45	$ 760
Minimum [Member]
Risk-free interest rate		0.11%	1.56%
Expected volatility		99.24%	82.85%
Common stock price		$ 2.50	$ 295

STOCKHOLDERS DEFICIT (Details 1

STOCKHOLDERS DEFICIT (Details 1) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Warrants, Outstanding Beginning Balance	10,089	1,894
Warrants, Issued	83,262	486
Warrants, Exercised		(1,188)
Anti-Dilution Modifications	59,394	9,100
Forfeiture/Cancellations		(203)
Warrants, Outstanding Ending Balance	152,745	10,089
Warrants, Vested	152,745
Weighted Average Exercise Price, Outstanding beginning	$ 45	$ 355
Weighted Average Exercise Price, Outstanding ending	2.85	$ 45
Weighted Average Exercise Price, Vested	$ 2.85
Weighted Average Life Remaining, Outstanding Beginning	3 years 29 days	4 years 2 months 19 days
Weighted Average Life Remaining, Outstanding Ending	2 years 5 months 19 days	3 years 29 days
Weighted Average Life Remaining, Vested	2 years 5 months 19 days

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)	Feb. 12, 2021	Aug. 31, 2021	Mar. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Feb. 11, 2021
Percentages of preferred shares stated value		120.00%
Common stock issued for cashless warrant exercise (In Shares)				43,167		1,062
Common Stock shares issued				2,458,250	1,537,081	44,986
Series C Preferred Stock [Member]
Preferred stock series, description			the Board of Directors of the Corporation had authorized issuance of up to 150 shares of preferred stock, $0.001 par value per share, designated as Series C Convertible Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $1,200
Series B Preferred Shares [Member]
Common stock price							$ 0.001
Redemption price				125.00%
Preferred stock series, description				On February 11, 2021, the Board of Directors of the Corporation had authorized issuance of up to 350 shares of preferred stock, $0.001 par value per share, designated as Series B Convertible Preferred Stock. Each share of Preferred Stock shall have a par value of $0.001 per share and a stated value of $1,200
Conversion price per share				$ 0.05
Warrants [Member]
Class of Warrant or Right, Outstanding					152,738
Convertible Loan Agreement [Member]
Shares issued upon exercise of warrants, shares					60,000	486
Warrants renaimed					152,745	10,089
Converted shares					69,063	1,188
Warrant term					3 years	5 years
Convertible Loan Agreement [Member] | Warrant Agreement [Member]
Number of increased warrants as per the warrant agreement						4,549,975
Convertible Loan Agreement [Member] | Warrant One
Warrant descriptions					outstanding warrants were increased by 9,100 to reflect the terms of the warrant agreements
Common stock price					$ 0.004	$ 2.50
Class of Warrant or Right, Outstanding					76,372,446
Convertible Loan Agreement [Member] | Warrant Two [Member]
Class of Warrant or Right, Outstanding						5,044,260
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					8,214,286	531,247
Redemption price				125.00%
Class of warrant or right converted into common shares						594,051
BHP Capital [Member]
Preferred stock shares designated	350
Stock Issued During Period, Shares, Issued for Services	3,000
Net proceeds	$ 326,600
Preferred stock shares designated, amount	$ 350,000
Common stock price	$ 1,200
Fourth LLC [Member]
Preferred stock shares designated			150
Net proceeds			$ 141,049
Preferred stock shares designated, amount			$ 150,000
Common stock price			$ 0.001
Stated Value per share				1,200
Aggregate purchase price			$ 150,000
Cumulative dividends			10.00%
Common Stock shares issued				642,857
Maximum [Member] | Warrants [Member]
Common stock price					$ 1.45	$ 760
Minimum [Member] | Warrants [Member]
Common stock price					2.50	295
Minimum [Member] | Convertible Loan Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					0.0029	0.59
Maximum [Member] | Convertible Loan Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.0050	$ 3.09
April To September, 2020 [Member] | Minimum [Member]
Additional shares of common stock			642,857
Warrant descriptions					granted a total of 60,000 warrants to three of our board members at an exercise price of $2.00
Preferred stock shares designated							350

STOCKBASED COMPENSATION (Detail

STOCKBASED COMPENSATION (Details) - Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Warrants, Outstanding at the begining	7	7
Outstanding, ending period	7	7
Warrants, Vested	5
Weighted Average Exercise Price, Outstanding beginning	$ 13,125	$ 13,125
Weighted Average Exercise Price, Outstanding ending	13,125	$ 13,125
Weighted Average Exercise Price, Vested	$ 13,125
Weighted Average Life Remaining, Outstanding beginning		7 years 7 months 24 days
Weighted Average Life Remaining, Outstanding ending	5 years 7 months 20 days	6 years 7 months 24 days
Weighted Average Life Remaining, Vested	5 years 7 months 20 days

STOCKBASED COMPENSATION (Deta_2

STOCKBASED COMPENSATION (Details 1) - Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Annual dividend yield		0.00%	0.00%
Expected life (years)		3 years	5 years
Maximum [Member]
Risk-free interest rate	0.81%	0.29%	2.23%
Common stock price	$ 17	$ 9.50
Expected volatility	98.81%	106.51%	92.64%
Expected life (years)	10 years
Minimum [Member]
Risk-free interest rate	0.23%	0.11%
Common stock price	$ 11.5000	$ 1.45
Expected volatility	92.93%	95.27%
Expected life (years)	2 years 8 months 12 days

STOCKBASED COMPENSATION (Deta_3

STOCKBASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2020	Dec. 31, 2019	May 18, 2016
Allocated Share-based Compensation Expense		$ 102,081	$ 0
Fair value of warrants		$ 35,670
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 87.50
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		The options vest at a rate of 100 on each anniversary date of the respective grants
Stock Incentive Plan2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				27
Minimum [Member] | April To September, 2020 [Member]
Exercise price		$ 1.45
Warrants granted		23,262
Warrant descriptions		granted a total of 60,000 warrants to three of our board members at an exercise price of $2.00
Maximum [Member]
Exercise price		$ 3.50

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES
Federal	$ (250,771)	$ (272,800)
State and local	(69,671)	(75,792)
Valuation allowance	320,442	(348,592)
Net provision for income taxes	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES
Net operating loss carryover	$ 1,593,282	$ 1,347,378
Accrued management fees, related party	155,063	80,825
Valuation allowance	(1,748,345)	(1,427,903)
Net deferred tax asset	$ 0	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES
Tax at federal statutory rate	21.00%	21.00%
State, net of federal benefit	0.20%	0.90%
Change in temporary differences	(0.00%)	(0.00%)
Permanent differences	(20.20%)	(17.90%)
Valuation allowance	(0.90%)	(4.10%)
Provision for taxes	0.00%	0.00%

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Federal and state net operating carry forward loss			$ 6.5
Deferred income tax provision percent		21.00%	21.00%
Patents [Member]
Expiration period of finite-lived intangible assets	2026	2036
Domestic Country [Member]
Deferred income tax provision percent		21.00%
State And Local Jurisdiction [Member]
Deferred income tax provision percent		8.90%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

Nov. 10, 2021

Dec. 09, 2020

Mar. 11, 2020

Apr. 11, 2018

Jan. 08, 2021

Feb. 29, 2020

Feb. 28, 2021

Mar. 31, 2021

Sep. 30, 2020

Dec. 31, 2020

Nov. 30, 2021

Sep. 30, 2021

Feb. 12, 2021

Dec. 31, 2019

Common stock, shares outstanding

1,537,073

2,458,242

44,978

Common stock, shares authorized

12,000,000,000

6,000,000,000

1,200,000,000

Common Stock shares issued

1,537,081

2,458,250

44,986

Preferred stock shares outstanding

0

0

Debt conversion, converrted instrument, shares issued

699,863,854

14,000,000,000

Convertible Note [Member]

Debt conversion, converrted instrument, shares issued

623,404

Debt conversion, converrted instrument, amount

$ 947,575

Series A Preferred Stock [Member]

Preferred stock voting right

The Certificate of Amendment increased the voting power of the Series A Preferred Stock to 10,00 votes per share from 30 votes per share

Preferred stock shares outstanding

3,000,000

Purchase Agreements [Member]

Common Stock shares issued

3,000

Aggregate purchase price

$ 144,500

Principal amount

$ 157,150,000

Debt instrument descriptions

convertible into shares of the Company’s common stock at a conversion prices ranging from to 60% to 61% of the average of the two lowest traded price of the Company’s common stock during the 15 trading days preceding the applicable conversion date

Maturity date description

The notes mature in February, 2021, bear interest at a rate of 8% per annum

Series B Preferred Stock [Member]

Stated Value per share

$ 1,200

Conversion price per share

$ 25

Preferred stock redemption terms

The Series B Preferred Stock (i) carries a quarterly dividend at the rate of 10% per annum, payable in cash or additional shares of Series B Preferred Stock, at the Company’s option, and (ii) may be redeemed by us, at its option, upon the payment of an amount equal to (a) $1,200 per share of Series B Preferred Stock

Creative Medical Health [Member]

Payments of related party

$ 50,000

Discount rate

30.00%

Common stock price per share

$ 0.0016

Debt conversion, converrted instrument, shares issued

19,711

Institutional Investor [Member] | Series B Preferred Stock [Member]

Aggregate purchase price

$ 350,000

Preferred stock shares designated

350,000

Contractor [Member] | Warrant One

Debt conversion, converrted instrument, shares issued

20,111

Common stock issued for cashless warrant exercise, shares

23,167

Subsequent Event [Member]

Common stock, shares outstanding

2,452,348

Common stock, shares authorized

50,000,000

50,000,000

Amendment description

Company filed an amendment to its Articles of Incorporation increasing the Company’s authorized shares of Common Stock to 25 billion from 6 billion.

Description of reverse stock split

1-for-500 reverse split of the both the Company’s authorized and outstanding shares of Common Stock